Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 37

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 37
---
)                 NET (LOSS)/PROFIT ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(380,791) $41,074  $(910,306) $(1,250,023)

 28Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

  Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   Nine months period ended September 30, 2025              REVENUE $11,302  $6,929,849  $-  $6,941,151                  COST OF REVENUE  (4,995)  (5,846,956)  -   (5,851,951)                 GROSS PROFIT  6,307   1,082,893   -   1,089,200                  OTHER INCOME                Dividend income   -   21,752   -   21,752 Interest income  63,646   10,468   -   74,114 Fair value gain on investments in equity securities  -   28,256   -   28,256 Gain on disposal of investments in equity securities  -   42,376   -   42,376 Reversal of expected credit losses  -   94,912   -   94,912 Others  10,919   136,312   -   147,231 TOTAL OTHER INCOME  74,565   334,076   -   408,641                  OPERATING EXPENSES                Sales and marketing  (86,275)  (1,577,214)  (37,202)  (1,700,691)Research and development  (39,572)  -   -   (39,572)General and administrative  (261,005)  (492,464)